Assahafa.com
The Moroccan Agency for Medicines and Health Products (AMMPS) denied reports circulating in certain media outlets regarding an alleged shortage of more than 600 medicines used to treat chronic illnesses.
The AMMPS, in its capacity as the national regulatory and oversight authority for the pharmaceutical sector, emphasized, in a statement, that the data available at the national level do not support the reported figures. It noted that if such a shortage were real, it would have significant repercussions on the functioning of the healthcare system, effects which have not been observed to date.
“It is important to highlight that temporary shortages of certain pharmaceutical products may occur, a phenomenon observed internationally, and mainly linked to pressures on supply chains, difficulties in accessing raw materials, or fluctuations in global markets,” the statement stressed.
The agency added that although these constraints are beyond the control of any single country, the Kingdom of Morocco proactively implements all necessary measures to mitigate their impact and ensure continuity of treatment for patients.
In coordination with the Ministry of Health and Social Protection and all relevant stakeholders, the AMMPS, through its Pharmaceutical Market Monitoring and Surveillance Service, maintains an ongoing mission to monitor and analyze the national supply of medicines, detect potential supply tensions in advance, and deploy rapid, targeted corrective actions to safeguard access to essential medicines.
This system has already proven effective in anticipating and proactively managing risk situations before they impact patients.
The agency also noted that, as part of the national strategy for pharmaceutical sovereignty, the AMMPS is implementing a structured policy centered on three priorities. These include boosting local production by increasing the share of medicines manufactured in Morocco to reduce dependency on imports and stabilize the market.
It also involves promoting competition and the development of generic drugs to limit monopolistic situations and ensure access to alternative therapies, in addition to securing the supply of vital medicines through proactive planning, source diversification, and the establishment of strategic stockpiles.
Furthermore, the AMMPS reaffirmed its continued commitment, in partnership with all stakeholders in the sector, to ensure the ongoing availability of essential medicines and to protect the health of citizens, which remains its top priority.
Source: map
